Relevant bibliographies by topics / Johnson City (N.Y.)

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Johnson City (N.Y.)'

Author: Grafiati
Published: 4 June 2021
Last updated: 30 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Johnson City (N.Y.).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Johnson City (N.Y.)"

1

Johnson-Roehr, Susan N. "Centering the Chārbāgh." Journal of the Society of Architectural Historians 72, no. 1 (March 1, 2013): 28–47. http://dx.doi.org/10.1525/jsah.2013.72.1.28.

Full text
Abstract:
In Centering the Chārbāgh: The Mughal Garden as Design Module for the Jaipur City Plan, Susan N. Johnson-Roehr argues that the privileging of a Hindu-Vedic worldview has had a significant effect on our understanding of Jaipur City’s history. Current interpretive approaches assume that the city’s patron, Sawai Jai Singh II, relied on the maṇḍala when shaping the city plan in the eighteenth century. The emphasis on the maṇḍala as governing device has encouraged historians to neglect other sources of Jaipur’s city plan. Specifically, scholars have not considered the role of the quadripartite Mughal paradise garden (chahār bāgh, Persian; chārbāgh, Hindi) in the planning of the city. Johnson-Roehr suggests that Jaipur’s spatial organization was defined by the chārbāgh rather than the navagraha or vāstu puruṣa maṇḍala, and demonstrates that the plan was a response to a specific chārbāgh, Jai Niwas Bagh, built by Sawai Jai Singh in 1713. Combining a rereading of eighteenth-century documents with an analysis of the physical characteristics of Jai Niwas Bagh, the author concludes that the chārbāgh was the most important element in the development of the rectilinear boulevards, bazaars, and walls that characterize Jaipur today.
APA, Harvard, Vancouver, ISO, and other styles
2

Lunning, Matthew A., Jason Gonsky, Jia Ruan, Adrienne A. Phillips, Melissa Pulitzer, Alison Moskowitz, Christiane Querfeld, Patricia L. Myskowski, Ariela Noy, and Steven M. Horwitz. "Pralatrexate in Relapsed/Refractory HTLV-1 Associated Adult T-Cell Lymphoma/Leukemia: A New York City Multi-Institutional Experience." Blood 120, no. 21 (November 16, 2012): 2735. http://dx.doi.org/10.1182/blood.v120.21.2735.2735.

Full text
Abstract:
Abstract Abstract 2735 Introduction: Adult T-cell lymphoma/leukemia (ATLL) is a mature T-cell malignancy associated with human T-cell lymphotropic virus -1 (HTLV-1) infection, which presents as aggressive (acute/lymphomatous) or indolent (chronic/smouldering) subtypes. The aggressive subtypes have a median survival of 6 months. Further, there is no established therapy for patients with relapsed/refractory disease. Pralatrexate is a dihydro-folate reductase inhibitor with high affinity for the reduced folate carrier type 1, a protein involved in trafficking of native folates. Pralatrexate given weekly at 30 mg/m2 for six of seven weeks was the first drug approved for use in relapsed/refractory peripheral T-cell lymphoma (PTCL) after demonstrating an overall response rate (ORR) of 29%. However, only one patient in the pivotal PROPEL study had ATLL. Approaches for relapsed/refractory PTCL are often applied to ATLL, as there is little data for this subtype. Here, we report a multi-institutional retrospective experience of pralatrexate in relapsed/refractory ATLL focusing on efficacy, durability, and toxicity. Methods: To investigate the therapeutic benefit and toxicity profile of pralatrexate we reviewed all patients with relapsed/refractory ATLL treated with pralatrexate on published trials or treated off study between 2005 and 2012 at three New York City institutions. Individual chart review was performed to report clinicopathologic features, treatment outcomes, and toxicity assessments. An event was defined as toxicity from pralatrexate resulting in discontinuation, progression, or death. Results: We identified 21 patients with relapsed/refractory ATLL treated with pralatrexate. Patient characteristics were: median age 52 (range 37–74); male:female 9:12; Region of origin was Caribbean-18, non-Caribean-3. Subtype at diagnosis of ATLL was: Acute/Lymphomatous-17 and Smouldering/Chronic-4. The median number prior treatments were 1 (range 0–5). Seven patients were treated on pralatrexate developmental clinical trials with one patient on the pivotal phase II PROPEL study. The median dose and number of treatments administered were 30 mg/m2 (range 15–45) and 4 (range 1–53) respectively. The ORR in patients evaluable for response (N=16) was 19% (2:PR; 1:CR) with an intent-to-treat (N=20) ORR was12% in patients with any exposure to pralatrexate. The median duration of response was 15 weeks (range 11–83). The median event free survival (EFS) was 6 weeks (range 1 to 90). One patient continues on pralatrexate without toxicity and has yet to be evaluated for response. Four patients (19%) developed findings consistent with Stevens-Johnson Syndrome (SJS) after 1 (N=2) or 2 (N=2) doses of pralatrexate. One additional patient developed a papular rash after pralatrexate; no biopsy was obtained. In the four patients with SJS, one had skin involvement of ATLL at diagnosis and at the time of pralatrexate, two had cutaneous ATLL lesions at the time of pralatrexate, and one did not have any cutaneous ATLL. Dermal apoptosis of tumor was not assessed in any of the cases. Seven patients (33%) developed clinically significant mucositis with two cases in patients with SJS. Conclusion: ATLL is a rare and difficult disease to manage. In our retrospective experience in relapsed/refractory ATLL, pralatrexate appears to have inferior ORR and much shorter EFS when compared to other PTCL subtypes. Notably, the risk of SJS, even without cutaneous involvement by lymphoma, may be higher in ATLL. In early phase studies of pralatrexate skin erosions were also seen in patients with PTCL with cutaneous involvement, including one cases of an ATLL patient with in vivo evidence of apoptosis of cutaneous tumor cells, but no cases of SJS were reported. A dedicated phase II study of pralatrexate in relapsed/refractory ATLL is planned by the Japan Clinical Oncology Group. Disclosures: Horwitz: Seattle Genetics: Consultancy, Research Funding; Allos: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; Bristol-Myers Squibb: Consultancy; Genzyme: Consultancy; Kyowa Hakko Kirin Pharma: Consultancy; Johnson & Johnson: Consultancy; Infinity Pharmaceuticals, Inc.: Research Funding.
APA, Harvard, Vancouver, ISO, and other styles
3

Gladman, D. D., P. J. Mease, P. Bird, E. Soriano, S. D. Chakravarty, M. Shawi, S. Xu, et al. "AB0894 Efficacy and Safety of Guselkumab in Biologic-Naïve Patients With Active Axial Psoriatic Arthritis: Study Design of a Phase 4, Randomized, Double-Blind, Placebo-Controlled Trial." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 1574–75. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1551.

Full text
Abstract:
BackgroundEstablished criteria for classifying axial psoriatic arthritis (PsA) are lacking, and assessments of disease activity often rely on measures developed for ankylosing spondylitis (AS). There is an unmet need to systematically identify and measure efficacy of treatments for axial PsA patients (pts). Guselkumab (GUS), a selective interleukin (IL)-23p19 inhibitor, was efficacious in improving signs and symptoms of active PsA in 2 phase 3, randomized, placebo (PBO)-controlled studies: DISCOVER-1 and DISCOVER-2. In a post-hoc pooled analysis of DISCOVER-1&2 pts with investigator-confirmed sacroiliitis, GUS-treated pts had greater improvements in axial symptoms compared with PBO.1 Imaging in DISCOVER-1&2 was restricted to the sacroiliac (SI) joints, occurring prior to/at screening as confirmed by the investigator, and locally read.ObjectivesTo design a new, dedicated study to evaluate the effects of GUS on axial PsA prospectively.MethodsCumulative evidence from DISCOVER-1&2, including exposure–response relationship, covariate adjustment for modest baseline imbalances across treatment groups, subgroup analyses, and comparisons within and across these studies, was considered in designing a new trial. Data from the pivotal registrational studies suggest similar efficacy with GUS every-4-weeks (Q4W) and Q8W regimens in treating PsA signs and symptoms, including symptoms of axial involvement. Power calculations were based on mean changes in Bath AS Disease Activity Index (BASDAI) scores in DISCOVER-1&2.ResultsThe phase 4, randomized, PBO-controlled STAR study is specifically designed to prospectively assess efficacy outcomes in PsA pts with magnetic resonance imaging (MRI)-confirmed axial inflammation. Based on observed mean (SD) changes from baseline in BASDAI score from DISCOVER-1&2 (Table 1), 405 pts, randomized (1:1:1) to GUS Q4W, GUS at W0, W4, then Q8W, or PBO →GUS Q8W at W24, are planned for enrollment (Figure 1). STAR eligibility criteria include PsA ≥6 months and active disease (≥3 swollen & ≥3 tender joints, C-reactive protein [CRP] ≥0.3 mg/dL) despite prior non-biologic disease-modifying antirheumatic drugs, apremilast, and/or non-steroidal anti-inflammatory drugs. Pts will be naïve to biologics and Janus kinase inhibitors and have BASDAI ≥4, spinal pain score (visual analog scale [VAS]) ≥4, and screening MRI-confirmed axial disease (positive spine and/or SI joints defined as centrally read Spondyloarthritis Research Consortium of Canada [SPARCC] score ≥3). Follow-up MRIs of spine and SI joints will be obtained at W0, W24, and W52 and also centrally read, with readers blinded to treatment group and timepoint. Spinal/SI joint inflammation will be scored using the SPARCC method, with the former also assessed using the CAN-DEN method. The primary endpoint is mean change in BASDAI at W24; controlled (hierarchical) secondary endpoints, all at W24, include AS Disease Activity Score (ASDAS-CRP), Disease Activity Index for PsA (DAPSA), ≥40% improvement in Assessment in AS criteria (ASAS40), and mean changes in spine/SI joint SPARCC scores.Table 1.Power calculations for the primary endpoint in the Phase 4 STAR study.Historical trial data*Observed mean (SD) change in BASDAI from W0-24Effect sizePower(N=135; α=0.05)**PBO-1.28 (2.24)GUS 100 mg Q4W-2.51 (2.00)1.23>99%GUS 100 mg Q8W-2.61 (2.47)1.33>99%* From the pooled DISCOVER-1&2 trials**Power calculations based on N=135 per study group (1:1:1 randomization) and 2-sided significance of 0.05 using a 2-sample T-test assuming equal variancesBASDAI, Bath Ankylosing Spondylitis Disease Activity Index; GUS, guselkumab; PBO, placebo; Q4W, every 4 weeks; Q8W, every 8 weeks; SD, standard deviation; W, weekConclusionThe phase 4 STAR study will allow for an in-depth, prospective evaluation of the effects of selectively inhibiting the IL-23p19 subunit with GUS in pts with MRI-confirmed axial PsA.References[1]Mease, et al. Lancet Rheum. 2021;3(10):e715-e723.Disclosure of InterestsDafna D Gladman Consultant of: AbbVie, Amgen, BMS, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB, Grant/research support from: Abbvie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer and UCB, Philip J Mease Speakers bureau: AbbVie, Aclaris, Amgen, BMS, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Inmagene, Janssen, Novartis, Pfizer, SUN Pharma, and UCB, Consultant of: AbbVie, Aclaris, Amgen, BMS, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Inmagene, Janssen, Novartis, Pfizer, SUN Pharma, and UCB, Grant/research support from: AbbVie, Aclaris, Amgen, BMS, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Inmagene, Janssen, Novartis, Pfizer, SUN Pharma, and UCB, Paul Bird Speakers bureau: AbbVie, Eli Lilly, Gilead, Janssen, MSD, Pfizer, and UCB, Consultant of: Eli Lilly, Gilead, Janssen, Novartis, and Pfizer, Enrique Soriano Speakers bureau: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB, Consultant of: AbbVie, Janssen, Novartis, and Roche, Grant/research support from: AbbVie, Janssen, Novartis, Pfizer, Roche, and UCB, Soumya D Chakravarty Shareholder of: Johnson & Johnson, Employee of: Janssen Scientific Affairs, LLC, May Shawi Shareholder of: Johnson & Johnson, Employee of: Janssen Global Services, LLC, Stephen Xu Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Sean Quinn Shareholder of: Johnson & Johnson, Employee of: Janssen Scientific Affairs, LLC, Cinty Gong Shareholder of: Johnson & Johnson, Employee of: Janssen Scientific Affairs, LLC, Evan Leibowitz Shareholder of: Johnson & Johnson, Employee of: Janssen Scientific Affairs, LLC, Lai-Shan Tam Consultant of: Janssen, Pfizer, Sanofi, AbbVie, Boehringer Ingelheim, and Lilly, Grant/research support from: Amgen, Boehringer Ingelheim, Janssen, GSK, Novartis, and Pfizer, Philip Helliwell Speakers bureau: AbbVie, Janssen, and Novartis, Consultant of: Galapagos and Janssen, Grant/research support from: AbbVie, Janssen, and Pfizer, Arthur Kavanaugh Consultant of: Abbvie, Amgen, Bristol Myers Squibb, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB, Atul Deodhar Speakers bureau: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Glaxo Smith & Kline, Janssen, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Eli Lilly, Glaxo Smith & Kline, Novartis, Pfizer, and UCB, Mikkel Østergaard Speakers bureau: AbbVie, Boehringer-Ingelheim, Bristol Myers Squibb, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, Sandoz, Sanofi, and UCB, Consultant of: AbbVie, Boehringer-Ingelheim, Bristol Myers Squibb, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, Sandoz, Sanofi, and UCB, Grant/research support from: AbbVie, Bristol Myers Squibb, Celgene, and Novartis, Xenofon Baraliakos Speakers bureau: AbbVie, Biocad, Chugai, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Roche, and UCB, Consultant of: AbbVie, Biocad, Chugai, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Roche, and UCB, Grant/research support from: AbbVie, Biocad, Chugai, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Roche, and UCB
APA, Harvard, Vancouver, ISO, and other styles
4

Sickels, Carter. "Johnson City." Appalachian Heritage 42, no. 2 (2014): 34–52. http://dx.doi.org/10.1353/aph.2014.0029.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Saleh, Mansoor N., James B. Bussel, Raymond SM Wong, Balkis Meddeb, Abdulgabar Salama, Ali El-Ali, Erhard Quebe-Fehling, and Abderrahim Khelif. "Hepatobiliary and Thromboembolic Events during Long-Term E.X.T.E.N.Ded Treatment with Eltrombopag in Adult Patients with Chronic Immune Thrombocytopenia (ITP)." Blood 128, no. 22 (December 2, 2016): 1368. http://dx.doi.org/10.1182/blood.v128.22.1368.1368.

Full text
Abstract:
Abstract Introduction: ITP, characterized by a reduction in platelets leading to thrombocytopenia, which persists for >12 months is considered chronic (cITP). Eltrombopag is an oral thrombopoietin receptor agonist approved for treatment of patients with cITP aged ≥1 year refractory to other treatments (eg corticosteroids, immunoglobulins). The recently completed Phase III EXTEND (Eltrombopag eXTENded Dosing) study was a global, open-label, extension study of patients with cITP, who received eltrombopag or placebo in prior eltrombopag clinical studies. The primary objective of EXTEND was to describe the long-term safety and tolerability of eltrombopag treatment in these patients. Here, we examine the occurrence of hepatobiliary and thromboembolic events (TEEs) as adverse events (AEs) of special interest in this study. Methods :Adult patients (≥18 years old) diagnosed with cITP according to ASH/BCSH guidelines were enrolled and received eltrombopag starting at 50 mg/day. Dose was titrated to 25-75 mg per day or less often as required, based on individual platelet count responses (targeted range ≥50-200x109/L). Patients who received 2 years of treatment and transitioned off eltrombopag due to commercial availability of eltrombopag were considered to have completed the study, whether or not they continued treatment with eltrombopag. The primary endpoint included detection and documentation of investigator-reported AEs, which included hepatobiliary AEs and TEEs. Analyses were conducted using the safety population, defined as all subjects who entered the study and had taken at least one dose of the study medication. Results:302 patients were enrolled and received at least one dose of eltrombopag: 67% were female; 38% splenectomized; 49% aged 18-49 years. Median duration of exposure was 2.4 years (range, 2 days to 8.8 years) and mean average daily dose was 50.2 (range, 1-75) mg/day. Overall, 259/302 (86%) achieved platelet counts of ≥50×109/L at least once during the study and 126/248 (51%) patients maintained continuous platelet counts ≥50×109/L for at least 31 weeks. Incidence of bleeding symptoms (WHO grades 1-4) generally decreased over time in patients with available data, from 57% (n=171/302) at baseline to 16% at 1 year (n=13/80), and 21% (12/58) at 2 years. 45 (15%) patients experienced at least one hepatobiliary AE, with the highest incidence within the first year of treatment (Figure A). AEs of increased ALT or AST led to the discontinuation of five and three patients, respectively and four patients discontinued due to an AE of increased blood bilirubin. Nine patients experienced ALT and/or AST >3 x upper limit of normal (ULN) and total bilirubin >1.5xULN. 19 (6.3%) patients experienced a total of 23 TEEs. Most events occurred in the first year (Figure B), and none after year 4. TEEs included deep vein thrombosis (n=6), cerebral infarction (stroke) [n=3], myocardial infarction (n=4), transient ischemic attack (n=2), others (n=8, 1 occurrence of each). A clear association with elevated platelet counts was not observed. Platelets >200x109/L at the time of the TEE were recorded in 8/19 patients; 6/19 experienced the TEE at or shortly after achieving their maximum platelet count. In total, 10 patients discontinued because of TEEs. Conclusions: Long-term treatment with eltrombopag in patients with cITP led to sustained platelet increases and reduced bleeding symptoms. The highest incidences of hepatobiliary AEs and TEEs occurred during the first year of treatment, though several events were recorded after 3 years of therapy. Long-term eltrombopag therapy was well-tolerated with a positive benefit-risk relationship in adults with cITP, with decreasing events after the first year of treatment. Disclosures Saleh: GSK: Consultancy, Research Funding, Speakers Bureau. Bussel:Amgen, Novartis & GSK: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Boehringer Ingleheim, Prophylix Pharma, Protalex, Rigel Pharmaceuticals: Research Funding; Momenta Pharmaceuticals, Novartis, Prophylix Pharma, Protalex, Rigel Pharmaceutical: Membership on an entity's Board of Directors or advisory committees; UptoDate: Patents & Royalties; Physicians Education Resource: Speakers Bureau. Wong:Bayer, Biogen-Idec and Novartis: Consultancy; Bayer, Biogen-Idec, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Merck Sharp & Dohme, Novartis, Pfizer, and Roche: Research Funding; Biogen-Idec and Novartis: Membership on an entity's Board of Directors or advisory committees. El-Ali:Novartis: Employment. Quebe-Fehling:Novartis: Employment.
APA, Harvard, Vancouver, ISO, and other styles
6

Hyman, Larry M. "Nasal consonant harmony at a distance the case of Yaka." Studies in African Linguistics 24, no. 1 (June 1, 1995): 6–30. http://dx.doi.org/10.32473/sal.v24i1.107408.

Full text
Abstract:
In a number of Bantu languages the [d-l] reflex of Proto-Bantu *-Vd- suffixes alternates with [n] when the consonant of the preceding syllable is nasal, e.g., /dim-id-/ 'cultivate for' ~ [dim-in-]. Because these Bantu languages do not allow nasalized vowels, it is necessary to view such assimilation as operating "at a distance" [Poser 1983], with the intervening vowel(s) being transparent. Transvocalic nasal consonant harmony (NCR) is widespread within Bantu [Greenberg 1951], and was repeatedly cited by phonologists in the 1970's, e.g., from Luba [Howard 1972, Johnson 1972] and Lamba [Kenstowicz and Kisseberth 1979]. In this paper I treat a more extensive and dramatic case of NCR at a distance in Yaka, a language spoken in Zaire. In this language /-Vd-/ suffixes are realized [-Vn-] even when the triggering nasal consonant is not in the immediately preceding syllable, e.g., /-miituk-id-/ 'sulk for' ~ [miituk-in-] (cf. Ao [1991], Piggott [1993] and Odden [1994], who cite parallel facts from Kongo). I begin by documenting the pervasiveness of the (stem-level) nasal harmony effects in the language, which therefore require a phonological analysis (vs. one involving allomorphy). Discussion centers around the problem of why voiceless and prenasalized consonants should be transparent to NCR.
APA, Harvard, Vancouver, ISO, and other styles
7

Tankard, P. "Johnson and the Walkable City." Eighteenth-Century Life 32, no. 1 (January 1, 2008): 1–22. http://dx.doi.org/10.1215/00982601-2007-009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Shouse, Geoffrey, Sylvia O. Dulan, Jamie Wagner, Michelle Mott, Alex Ly, Donna Ujiiye, Mary C. Clark, et al. "Real World Evaluation of Deviation Outcomes in an Immune Effector Cell Quality Program." Blood 136, Supplement 1 (November 5, 2020): 10. http://dx.doi.org/10.1182/blood-2020-143412.

Full text
Abstract:
Introduction City of Hope (COH) was one of the first institutions to be granted Immune Effector Cell (IEC) Therapy accreditation by the Foundation for the Accreditation of Cellular Therapy, which supports our mission to provide safe, high quality patient care through expanded standardization. As part of the accreditation requirements, COH expanded established processes developed to monitor standard of care (SOC) deviations for the Hematopoietic Cell Transplantation Program to our IEC Clinical Program. As part of process improvement, we monitored our IEC Quality program to determine if there were any outcome changes as a result of deviations. Therefore, we performed a retrospective analysis of electronically submitted SOC deviations for patients treated with commercially available chimeric antigen receptor (CAR) T cell products (tisagenlecleucel or axicabtagene ciloleucel [Axi-cel]) between December 2017- March 2020 at COH. Methods During the reporting timeframe, 122 patients were planned to be treated with an IEC product. We retrieved 28 requests for SOC deviations from our electronic database for 24 of 122 patients. We analyzed for volume, trends and patient outcomes of submitted deviation requests, including trends in type of deviation, transfer to the intensive care unit (ICU), length of inpatient hospital stay and safety outcomes at 30 days post infusion. Patients who did not receive their SOC product for any reason during the reporting timeframe, or were lost to follow-up were excluded from the outcomes analysis. Results Sixteen of 24 patients were planned to be treated with SOC Axi-cel and 8 of 24 patients were planned to be treated with tisagenlecleucel; only 19 of 24 patients (10 women and 9 men) underwent infusion with their respective SOC product, 15 with Axi-cel and 4 with tisagenlecleucel. Five of 24 patients, including 1 Axi-cel and 4 tisagenlecleucel patients were excluded due to change in medical condition or infusion after the reporting timeframe. We identified elevated creatinine levels as the most common reason for SOC deviation requests for patients to be treated with tisagenlecleucel (4 of 8 patients), while deviations relating to rest days between lymphodepletion and CAR T cell infusion were the most common submitted deviations for patients planned to be treated with Axi-cel (9 of 16 patients). We also descriptively compared patients who required SOC deviations to a cohort of patients (n=98) who did not require deviations and were treated with either axicabtagene ciloleucel (n=86) or tisagenlecleucel (n=12) during the same timeframe. Eight of 98 (8%) of patients who did not have requests for SOC deviation were transferred to the ICU compared to 4 of 19 (21%) patients who required SOC deviations. Seventeen of 19 and 94 of 98 patients were discharged. The median length of inpatient hospital stay post infusion for SOC deviations cohorts who were discharged was 16 days (11-40) and 15 days (8-100) for non-SOC deviations patients. When we descriptively compared survival outcomes at 30 days post infusion, we found that all (4 of 4) patients who required SOC deviations and received tisagenlecleucel survived compared to 11 of 12 patients without SOC deviations. For patients who received Axi-cel, 14 of 15 patients with SOC deviations survived at day 30 post infusion compared to 85 of 86 patients without SOC deviations. The response to treatment and toxicities will be reported at the meeting. Conclusion These data suggest that careful selection of patients who may benefit from SOC deviations and still receive their infusion may not negatively affect survival outcomes at 30 days. The SOC deviation review process offers physicians a forum to evaluate non-SOC eligible cases and advise on SOC policy changes. While preliminary, our quality review identifies a role for comprehensive analysis of all IEC SOC deviations as part of standard practice, especially as the field of cellular immunotherapy expands to include more SOC cellular products. Overall, further monitoring of SOC deviations in real world patient populations treated with commercially available IEC products will allow us to continue to support patient safety, assess patient care management practices, expand patient access, meet accreditation standards and monitor SOC practice changes while advancing the field of cellular immunotherapy. Disclosures Shouse: Kite Pharma: Honoraria, Speakers Bureau. Mott:Janssen/Johnson & Johnson: Consultancy; Juno/BMS: Consultancy. Budde:Gilead Sciences: Consultancy; AstraZeneca: Research Funding; Merck: Research Funding; Mustang Therapeutics: Research Funding; Kite, a Gilead Company: Consultancy; Roche: Consultancy; Amgen: Research Funding.
APA, Harvard, Vancouver, ISO, and other styles
9

Schanz, Julie, Fischer Stephanie, Claudia Haferlach, Georgia Bardi, Marilyn L. Slovak, Virginie Eclache, Bertil Johansson, et al. "Unrelated Clones In Myelodysplastic Syndromes and Acute Myeloid Leukemia - Characterization and Prognostic Relevance." Blood 116, no. 21 (November 19, 2010): 4022. http://dx.doi.org/10.1182/blood.v116.21.4022.4022.

Full text
Abstract:
Abstract Abstract 4022 Introduction: The occurrence of cytogenetically-unrelated clones is a rare but recognized event in haematological malignancies that may appear at either presentation or in further progression of disease. As yet, little is known about the composition and prognostic relevance of unrelated clones in MDS and AML. The aim of this retrospective study was to analyze cases of unrelated clones in a large, multicentric and international study to further characterize their clinical relevance in myeloid disorders. Patients/Methods: A total of 95 patients with unrelated clones and their corresponding clinical data were collected from 10 different databases: MLL (n=30), German-Austrian-Swiss (16), Athens (11), City of Hope (10), Bobigny (6), Lund (5), Tokyo (5), Spanish (4), IMRAW (3), and Dortmund (2). 77 pts. (81.1%) had a diagnosis of primary MDS, 5 (5.3%) t-MDS, 9 (9.5%) de novo AML, and 4 (4.2%) AML following MDS. Abnormalities detected FISH only were excluded. Unrelated clones were defined as two abnormal clones that were not evolvable from each other. Overall survival and the risk of AML transformation was calculated. For comparison MDS cases without unrelated clones were included from the international MDS database, including 2901 pts. with primary MDS. Result: Two unrelated clones were seen in 80 pts. (84%), three in 14 (15%) and five in 1 patient (1%). The majority of cases showed one aberration per clone (84.5%). The most frequent single aberration was +8 (43.2%), followed by del(5q) (28.4%). Other anomalies were -7/del(7q) (14.7%), -Y (12.6%), del(20q) (9.5%), +21 (7.4%), i(17q) (5.3%) and del(9q) (5.3%). Complex aberrations were identified in 3/95 cases (3.2%) only. Patients with unrelated clones showed an overrepresentation of +8 (p<0.0001), -Y (p=0.031) and i(17q) (p=0.013) in comparison to patients without unrelated clones. A combination of del(5q) and +8 was observed in 13/95 (13.7%) cases. Other recurrent combinations were: -7/+8 (n=2; 2.1%), -Y/del(5q) (n=2; 2.1%) and del(5q)/20q- (n=2; 2.1%). Translocations occurred only in single cases. The median survival of all patients with unrelated clones was 26.5 months, a finding consistent with an intermediate prognosis. Patients with a +8 clone and a clone with any other aberration showed a median survival of 21.0 months. Combinations of del(5q)/+8 (median 45.8 months) as compared to isolated del(5q) showed no significant difference in survival and in comparison to cases with +8 plus a clone with any other aberration, led to a significantly better survival (p=0.004). Summary: Our data presents the largest series of MDS/AML patients showing unrelated clones published to date. While the most frequent combination del(5q)/+8 is associated with a favourable outcome, all other combinations have to be assigned to the intermediate risk group until further distinct combinations can be evaluated. Further data will be presented in detail. Disclosures: Haferlach: MLL Munich Leukemia Laboratory: Employment, Equity Ownership. Slovak:PerkinElmer: Employment. Ohyashiki:Nippon Shinyaku Co., Ltd.: Research Funding. Giagounidis:Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees. Bennett:Johnson & Johnson: Consultancy.
APA, Harvard, Vancouver, ISO, and other styles
10

Schafer, Frederick C., Joseph F. Bridger, and Noral D. Stewart. "St. Mary’s Catholic Church, Johnson City, TN." Journal of the Acoustical Society of America 119, no. 5 (May 2006): 3370. http://dx.doi.org/10.1121/1.4786533.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Johnson City (N.Y.)"

1

Division, Johnson City GIS. "Johnson City Annexations, 1960-2003." Digital Commons @ East Tennessee State University, 2003. https://dc.etsu.edu/rare-maps/12.

Full text
Abstract:
Produced by the Johnson City GIS Division on September 9, 2003, this map denotes the annexations of Johnson City and the surrounding area from 1960 to 2003. The map scale indicates a ratio of 1:24,000. In the text box on the left side, the ID, date, and annexation names are listed. As part of the legend, each 5 year annexation period is color coded. This map was donated by the Johnson City GIS Division and now resides in the map collection of Sherrod Library's Government Information, Law and Maps Department.
https://dc.etsu.edu/rare-maps/1011/thumbnail.jpg
APA, Harvard, Vancouver, ISO, and other styles
2

Division, Johnson City GIS. "Johnson City, Tennessee Streets, 2003." Digital Commons @ East Tennessee State University, 2003. https://dc.etsu.edu/rare-maps/13.

Full text
Abstract:
Produced by the Johnson City GIS Division on September 9, 2003, this map denotes the streets of Johnson City. The legend includes fire stations, neighborhoods, and schools. A city street index is also included. The map was designed by Gregory Plumb, GIS Coordinator and Ann Howland, GIS Database Specialist. This map was donated by the Johnson City GIS Division and now resides in the map collection of Sherrod Library's Government Information, Law and Maps Department.
https://dc.etsu.edu/rare-maps/1012/thumbnail.jpg
APA, Harvard, Vancouver, ISO, and other styles
3

Johnson, City GIS Division. "Johnson City Annexations, 1960-1994." Digital Commons @ East Tennessee State University, 1994. https://dc.etsu.edu/rare-maps/56.

Full text
Abstract:
Produced by the Johnson City GIS Division on June 17, 1994. This map denotes the annexations of Johnson City and the surrounding area from 1960 to 1994. The map scale indicates a ratio of 1:24,000. In the text box on the left side, the ID, date, and annexation names are listed. As part of the legend, each 5 year annexation period is color coded.
https://dc.etsu.edu/rare-maps/1055/thumbnail.jpg
APA, Harvard, Vancouver, ISO, and other styles
4

Division, Johnson City GIS. "Johnson City Annexations, 1960-2000." Digital Commons @ East Tennessee State University, 2001. https://dc.etsu.edu/rare-maps/57.

Full text
Abstract:
Produced by the Johnson City GIS Division on June 19, 2001, this map denotes the annexations of Johnson City and the surrounding area from 1960 to 2000. The map scale indicates a ratio of 1:24,000. In the text box on the left side, the ID, date, and annexation names are listed. As part of the legend, each 5 year annexation period is color coded. Scale - 1"= 2000’
https://dc.etsu.edu/rare-maps/1056/thumbnail.jpg
APA, Harvard, Vancouver, ISO, and other styles
5

Division, Johnson City GIS. "Johnson City Annexations, 1960-2006." Digital Commons @ East Tennessee State University, 2006. https://dc.etsu.edu/rare-maps/58.

Full text
Abstract:
Produced by the Johnson City GIS Division on May 8, 2006, this map denotes the annexations of Johnson City and the surrounding area from 1960 to 2006. The map scale indicates a ratio of 1:24,000. In the text box on the left side, the ID, date, and annexation names are listed. As part of the legend, each 5 year annexation period is color coded. 1 in= 2000’
https://dc.etsu.edu/rare-maps/1057/thumbnail.jpg
APA, Harvard, Vancouver, ISO, and other styles
6

Division, Johnson City GIS. "Johnson City Zoning Map - 2000." Digital Commons @ East Tennessee State University, 2000. https://dc.etsu.edu/rare-maps/59.

Full text
Abstract:
Zoning map for Johnson City, Tennessee created February 18, 2000 by Johnson City GIS. The guide to zoning districts can be found in a box on the lower left corner. The color coded key and additional information is included along the bottom. Arterial and collector streets are also denoted using empty versus solid circles. Scale - 1" = 2000'
https://dc.etsu.edu/rare-maps/1058/thumbnail.jpg
APA, Harvard, Vancouver, ISO, and other styles
7

Division, Johnson City GIS. "Johnson City Zoning Map - 2003." Digital Commons @ East Tennessee State University, 2003. https://dc.etsu.edu/rare-maps/60.

Full text
Abstract:
Zoning map for Johnson City, Tennessee created November 6, 2013 by Johnson City GIS. The guide to zoning districts can be found in a box on the lower left corner. The color coded key and additional information is included along the bottom. Arterial and collector streets are also denoted using empty versus solid circles. Scale - 1" = 2000'
https://dc.etsu.edu/rare-maps/1059/thumbnail.jpg
APA, Harvard, Vancouver, ISO, and other styles
8

Division, Johnson City GIS. "Johnson City Zoning Map - 2007." Digital Commons @ East Tennessee State University, 2007. https://dc.etsu.edu/rare-maps/61.

Full text
Abstract:
Zoning map for Johnson City, Tennessee created March 9, 2007 by Johnson City GIS. The guide to zoning districts can be found in a box on the lower left corner. The color coded key and additional information is included along the bottom. Arterial and collector streets are also denoted using empty versus solid circles. Scale - 1" = 2500'
https://dc.etsu.edu/rare-maps/1060/thumbnail.jpg
APA, Harvard, Vancouver, ISO, and other styles
9

Division, Johnson City GIS. "Johnson City Zoning Map - 2021." Digital Commons @ East Tennessee State University, 2021. https://dc.etsu.edu/rare-maps/62.

Full text
Abstract:
Zoning map for Johnson City, Tennessee created July 2, 2021 by Johnson City GIS. The guide to zoning districts can be found in a box on the side of map. The color coded key and additional information is included. An inset of downtown is featured in the bottom left corner. Scale 1" = 2000'
https://dc.etsu.edu/rare-maps/1061/thumbnail.jpg
APA, Harvard, Vancouver, ISO, and other styles
10

Division, Johnson City GIS. "Johnson City Street Network - 1993." Digital Commons @ East Tennessee State University, 1993. https://dc.etsu.edu/rare-maps/63.

Full text
Abstract:
Street map of Johnson City, Tennessee created on June 18, 1993 by Johnson City GIS. This map denotes the highways and roads of Johnson City as they were in 1993. No scale is included.
https://dc.etsu.edu/rare-maps/1062/thumbnail.jpg
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Johnson City (N.Y.)"

1

Johnson City. Charleston, SC: Arcadia, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Remembering Johnson City. Charleston, SC: History Press, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Stahl, Ray. Greater Johnson City: A pictorial history. 2nd ed. Norfolk (5659 Virginia Beach Blvd., Norfolk 23502): Donning Co., 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Jakarta undercover: Sex n' the city. Yogyakarta: Galang Press, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Sawai, Gloria. A song for Nettie Johnson. Regina, Sask: Coteau Books, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Johnson, Edgar Nathaniel. Fünf Monate in Berlin: Briefe von Edgar N. Johnson aus dem Jahre 1946. München: De Gruyter Oldenbourg, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Eschebach, Hans. Pompeji, vom 7. Jahrhundert v. Chr. bis 79 n. Chr. Köln: Böhlau, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Weimer, George N. George N. Weimer: Mayor and first city manager of Orange. [Fullerton, Calif.]: California State University, Fullerton, Oral History Program, Orange Community History Project, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sullivan, Michael. Escapade Johnson and the witches of Belknap County. Exeter, N.H: Publishing Works, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Sorkin, Michael. Local code: The constitution of a city at 42°N latitude. New York, N.Y: Princeton Architectural Press, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Johnson City (N.Y.)"

1

Varney, Andrew. "Country and City, the Choice of Life: Dr Johnson." In Eighteenth-Century Writers in their World, 197–220. London: Macmillan Education UK, 1999. http://dx.doi.org/10.1007/978-1-349-27763-6_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Beeber, Steven Lee. "Juidos ‘n’ Decaf Italians: Irony, Blasphemy, and Jewish Shtick." In Sounds and the City, 76–90. London: Palgrave Macmillan UK, 2014. http://dx.doi.org/10.1057/9781137283115_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Manfredi, Francesco, and Dario Costi. "Sustainable Urban Regeneration: A Literature Review (A. Fanfoni, E. Ortolan, N. Raimo)." In The City Project, 15–24. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-20368-8_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wagg, Stephen. "‘Why I Decided to Pretend I was American, I Will Never Know’: Rock ‘n’ Roll and ‘The Sixties’ in an English Town." In Sounds and the City, 93–112. London: Palgrave Macmillan UK, 2014. http://dx.doi.org/10.1057/9781137283115_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Aiestaran, Jokin, Jasone Cenoz, and Durk Gorter. "12. Multilingual Cityscapes: Perceptions and Preferences of the Inhabitants of the City of Donostia-San Sebastia´n." In Linguistic Landscape in the City, edited by Elana Shohamy, Eliezer Ben-Rafael, and Monica Barni, 219–34. Bristol, Blue Ridge Summit: Multilingual Matters, 2010. http://dx.doi.org/10.21832/9781847692993-014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lee, Jan. "Pride and Prejudice: Teachers, Class and an Inner-City Infants School." In Routledge Library Editions: Education Mini-Set N Teachers & Teacher Education Research 13 vols, Vol226:90—Vol226:116. London: Routledge, 2021. http://dx.doi.org/10.4324/9780203125526-133.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Clapp, James A. "N." In The City, 265–69. Routledge, 2017. http://dx.doi.org/10.4324/9781315131283-14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

"city [n]." In Encyclopedic Dictionary of Landscape and Urban Planning, 126. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-76435-9_1838.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

"city edge [n]." In Encyclopedic Dictionary of Landscape and Urban Planning, 126. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-76435-9_1847.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

"city scenery [n]." In Encyclopedic Dictionary of Landscape and Urban Planning, 127. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-76435-9_1858.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Johnson City (N.Y.)"

1

Canale, Tony D., Gerard Drohen, and James L. Kaufman. "Design and Construction of the Foundations for the Watauga Raw Water Intake Facility in Karstic Limestone near the City of Johnson City, TN." In 10th Multidisciplinary Conference on Sinkholes and the Engineering and Environmental Impacts of Karst. Reston, VA: American Society of Civil Engineers, 2005. http://dx.doi.org/10.1061/40796(177)38.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Vicek, Brian L., Robert C. Hendricks, and Erwin V. Zaretsky. "Probabilistic Analysis for Comparing Fatigue Data Based on Johnson-Weibull Parameters." In ASME 2007 International Design Engineering Technical Conferences and Computers and Information in Engineering Conference. ASMEDC, 2007. http://dx.doi.org/10.1115/detc2007-34849.

Full text
Abstract:
Probabilistic failure analysis is essential when analysis of stress-life (S-N) curves is inconclusive in determining the relative ranking of two or more materials. In 1964, L. Johnson published a methodology for establishing the confidence that two populations of data are different. Simplified algebraic equations for confidence numbers were derived based on the original work of L. Johnson. Using the ratios of mean life, the resultant values of confidence numbers deviated less than one percent from those of Johnson. It is possible to rank the fatigue lives of different materials with a reasonable degree of statistical certainty based on combined confidence numbers. These equations were applied to rotating beam fatigue tests that were conducted on three aluminum alloys at three stress levels each. These alloys were AL 2024, AL 6061, and AL 7075. The results were analyzed and compared using ASTM Standard E739-91 and the Johnson-Weibull analysis. The ASTM method did not statistically distinguish between AL 6010 and AL 7075. Based on the Johnson-Weibull analysis confidence numbers greater than 99 percent, AL 2024 was found to have the longest fatigue life, followed by AL 7075, and then AL 6061. The ASTM Standard and the Johnson-Weibull analysis result in the same stress-life exponent p for each of the three aluminum alloys at the median or L50 lives.
APA, Harvard, Vancouver, ISO, and other styles
3

Landge, Shruti, Vivek Saraswat, Srisht Fateh Singh, and Udayan Ganguly. "n-Oscillator Neural Network based Efficient Cost Function for n-city Traveling Salesman Problem." In 2020 International Joint Conference on Neural Networks (IJCNN). IEEE, 2020. http://dx.doi.org/10.1109/ijcnn48605.2020.9206856.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hoffman, B. Todd, and Jeffrey M. Rutledge. "Mechanisms for Huff-n-Puff Cyclic Gas Injection into Unconventional Reservoirs." In SPE Oklahoma City Oil and Gas Symposium. Society of Petroleum Engineers, 2019. http://dx.doi.org/10.2118/195223-ms.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hamideh Noory, Hamid Zare Abyane, Hamideh Noory, and Abdol-Majid Liaghat. "Application of DRAINMOD-N Model for Predicting Nitrate-N in Paddy Rice Fields under Controlled Drainage in a Costal Region of Iran." In 9th International Drainage Symposium held jointly with CIGR and CSBE/SCGAB Proceedings, 13-16 June 2010, Québec City Convention Centre, Quebec City, Canada. St. Joseph, MI: American Society of Agricultural and Biological Engineers, 2010. http://dx.doi.org/10.13031/2013.32124.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Fan, Ya-fu, Jun-sheng Ning, Jie Chen, and Xin-zhong Cui. "Physical Sense of the Plastic Modulus of Metallic Materials at High Strain-Rates." In ASME 2012 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/imece2012-86580.

Full text
Abstract:
In this paper, impact experiments in nitrogen alloyed austenitic steel (high-N steel) and 685 steel were carried out with the split Hopkinson pressure bar (SHPB) apparatus. It can be found from the experiments that the plastic modulus and the strain-rate sensitivity exponent are two main factors of holding together materials dynamic steadiness at high strain-rates. In particular, the magnitude of plastic modulus indicated the ability with transferring stress-wave load in aspect of physical nature. The greater this value, the greater is absorbency of projectile dynamical energy for target material. This conclusion has been proved by fitting Johnson-Cook model parameters and correlative numerical calculation and microcosmic analysis. Continuing above thoughts, the estimation of terminal ballistics performance of target material using Johnson damage number and hardening damage number will be applied in engineering.
APA, Harvard, Vancouver, ISO, and other styles
7

Jadhav, Jvotsna J., Chetali R. Ayare, Akash S. Nalawade, and Rucha Pathari. "DINE ‘n’ FINE TABLE: An Interactive Platform for Food Industry." In 2018 International Conference on Smart City and Emerging Technology (ICSCET). IEEE, 2018. http://dx.doi.org/10.1109/icscet.2018.8537294.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Huanhuan Liu, Xiaoqing Yu, and Jing Lu. "Identifying top-n opinion leaders on local social network." In IET International Conference on Smart and Sustainable City 2013 (ICSSC 2013). Institution of Engineering and Technology, 2013. http://dx.doi.org/10.1049/cp.2013.1970.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Lu, J. "From the opposite to harmony: villag e vs. city – research on “village within city” i n booming China." In International Conference on Civil, Urban and Environmental Engineering. Southampton, UK: WIT Press, 2015. http://dx.doi.org/10.2495/cuee140781.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Clark, Bruce J., and Marc J. Rogoff. "Economic Feasibility of a Plasma Arc Gasification Plant, City of Marion, Iowa." In 18th Annual North American Waste-to-Energy Conference. ASMEDC, 2010. http://dx.doi.org/10.1115/nawtec18-3502.

Full text
Abstract:
The City of Marion (“City”) and wastenotIowa, Inc. (WNI), along with other interested parties, has been considering the use of a plasma are gasification plant (“Plant”) as a technology that could reduce their future dependency on landfill disposal. As currently envisioned, the Plant would serve Linn County, including the City and the University of Iowa (“UI”) Oakdale research campus, located in Johnson County. In the next step of their evaluations, the City along with the Iowa Department of Natural Resources (DNR) has commissioned SCS Engineers (SCS) to perform a formal economic feasibility study of the Plant. The feasibility study included: •Assessing potential for other waste material other than municipal solid waste in the region as supplemental plant feedstock. •Assessing potential markets for the plasma plant byproducts. •Determining the feasibility, requirements and costs related to an interconnect with the power utility grid. •Assessing the option that the UI could potentially be the exclusive power customer for the Plant. •Developing a pro-forma model so that various options can be evaluated for the Plant capacity and material and energy output configurations over an assumed initial 20-year contract operating phase, including; –Production of syngas for conversion to electrical power –Production of syngas for direct use and conversion to fuel products –Production of insulation from slag to enhance project revenues. •Determining the potential economic impact of the Plant on the region.
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Johnson City (N.Y.)"

1

Nashold, B., D. Rosenblatt, and J. Hau. Supplemental site inspection for Air Force Plant 59, Johnson City, New York, Volume 1: Investigation report. Office of Scientific and Technical Information (OSTI), August 1995. http://dx.doi.org/10.2172/116655.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Renner, Ernie. Best Manufacturing Practices: Report of Survey Conducted at the Tri-Cities, Tennessee/Virginia Region, Johnson City, TN. Fort Belvoir, VA: Defense Technical Information Center, January 2001. http://dx.doi.org/10.21236/ada397924.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Nashold, B., D. Rosenblatt, and D. Tomasko. Supplemental site inspection for Air Force Plant 59, Johnson City, New York, Volume 2: Appendices A-E. Office of Scientific and Technical Information (OSTI), August 1995. http://dx.doi.org/10.2172/116648.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Nashold, B., D. Rosenblatt, and J. Hau. Supplemental site inspection for Air Force Plant 59, Johnson City, New York, Volume 3: Appendices F-Q. Office of Scientific and Technical Information (OSTI), August 1995. http://dx.doi.org/10.2172/116654.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kodupuganti, Swapneel R., Sonu Mathew, and Srinivas S. Pulugurtha. Modeling Operational Performance of Urban Roads with Heterogeneous Traffic Conditions. Mineta Transportation Institute, January 2021. http://dx.doi.org/10.31979/mti.2021.1802.

Full text
Abstract:
The rapid growth in population and related demand for travel during the past few decades has had a catalytic effect on traffic congestion, air quality, and safety in many urban areas. Transportation managers and planners have planned for new facilities to cater to the needs of users of alternative modes of transportation (e.g., public transportation, walking, and bicycling) over the next decade. However, there are no widely accepted methods, nor there is enough evidence to justify whether such plans are instrumental in improving mobility of the transportation system. Therefore, this project researches the operational performance of urban roads with heterogeneous traffic conditions to improve the mobility and reliability of people and goods. A 4-mile stretch of the Blue Line light rail transit (LRT) extension, which connects Old Concord Rd and the University of North Carolina at Charlotte’s main campus on N Tryon St in Charlotte, North Carolina, was considered for travel time reliability analysis. The influence of crosswalks, sidewalks, trails, greenways, on-street bicycle lanes, bus/LRT routes and stops/stations, and street network characteristics on travel time reliability were comprehensively considered from a multimodal perspective. Likewise, a 2.5-mile-long section of the Blue Line LRT extension, which connects University City Blvd and Mallard Creek Church Rd on N Tryon St in Charlotte, North Carolina, was considered for simulation-based operational analysis. Vissim traffic simulation software was used to compute and compare delay, queue length, and maximum queue length at nine intersections to evaluate the influence of vehicles, LRT, pedestrians, and bicyclists, individually and/or combined. The statistical significance of variations in travel time reliability were particularly less in the case of links on N Tryon St with the Blue Line LRT extension. However, a decrease in travel time reliability on some links was observed on the parallel route (I-85) and cross-streets. While a decrease in vehicle delay on northbound and southbound approaches of N Tryon St was observed in most cases after the LRT is in operation, the cross-streets of N Tryon St incurred a relatively higher increase in delay after the LRT is in operation. The current pedestrian and bicycling activity levels seemed insignificant to have an influence on vehicle delay at intersections. The methodological approaches from this research can be used to assess the performance of a transportation facility and identify remedial solutions from a multimodal perspective.
APA, Harvard, Vancouver, ISO, and other styles
6

Delmer, Deborah P., Douglas Johnson, and Alex Levine. The Role of Small Signal Transducing Gtpases in the Regulation of Cell Wall Deposition Patterns in Plants. United States Department of Agriculture, August 1995. http://dx.doi.org/10.32747/1995.7570571.bard.

Full text
Abstract:
The combined research of the groups of Delmer, Levine and Johnson has led to a number of interesting findings with respect to the function of the small GTPase Rac in plants and also opened up new leads for future research. The results have shown: 1) The Rac13 protein undergoes geranylgeranlyation and is also translocated to the plasma membrane as found for Rac in mammals; 2) When cotton Rac13 is highly- expressed in yeast, it leads to an aberrant phenotype reminiscent of mutants impaired in actin function, supporting a role for Rac13 in cytoskeletal organization; 3) From our searches, there is no strong evidence that plants contain homologs of the related CDC42 genes found in yeast and mammals; 4) We have identified a rather unique Rac gene in Arabidopsis that has unusual extensions at both the N- and C-terminal portions of the protein; 5) New evidence was obtained that an oxidative burst characterized by substantial and sustained production of H202 occurs coincident with the onset of secondary wall synthesis in cotton fibers. Further work indicates that the H202 produced may be a signal for the onset of this phase of development and also strongly suggests that Rac plays an important role in signaling for event. Since the secondary walls of plants that contain high levels of lignin and cellulose are the major source of biomass on earth, understanding what signals control this process may well in the future have important implications for manipulating the timing and extent of secondary wall deposition. 6) When the cotton Rac13 promoter is fused to the reporter gene GUS, expression patterns in Arabidopsis indicate very strong and specific expression in developing trichomes and in developing xyelm. Since both of these cell types are engaged in secondary wall synthesis, this further supports a role for Rac in signaling for onset of this process. Since cotton fibers are anatomically defined as trichomes, these data may also be quite useful for future studies in which the trichomes of Arabidopsis may serve as a model for cotton fiber development; the Rac promoter can therefore be useful to drive expression of other genes proposed to affect fiber development and study the effects on the process; 7) The Rac promoter has also been shown to be the best so far tested for use in development of a system for transient transformation of developing cotton fibers, a technique that should have many applications in the field of cotton biotechnology; 8) One candidate protein that may interact with Rac13 to be characterized further in the future is a protein kinase that may be analogous to the PAK kinase that is known to interact with Rac in mammals.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Johnson City (N.Y.)' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography